title: Sarcoplasmic reticulum calcium release is stimulated and inhibited by daunorubicin and daunorubicinol.
abstract: Cardiac effects of anthracyclines or their metabolites may include both the stimulation and inhibition of Ca(2+) release from sarcoplasmic reticulum. In this study, the ability of daunorubicin and its primary metabolite, daunorubicinol, to stimulate and inhibit Ca(2+) release from canine sarcoplasmic reticulum (SR) vesicles was investigated. It was observed that both daunorubicin and daunorubicinol were several fold more potent at inhibiting than they were at stimulating SR Ca(2+) release. Respective IC50 inhibition of daunorubicin and daunorubicinol for caffeine-induced calcium release was 1.2 and 0.6 microM, and for spontaneous Ca(2+) release was 3 and 1 microM. EC50's for daunorubicin- and daunorubicinol-induced calcium release were 30 and 15 microM, respectively. Inhibition of either spontaneous or caffeine-induced SR Ca(2+) release was inversely related to the amount of Ca(2+) loaded into the SR before exposure to daunorubicin or daunorubicinol. The free-radical scavenger dithiothreitol did not attenuate the ability of anthracyclines to inhibit SR Ca(2+) release. A nonquinone daunorubicin derivative, 5-iminodaunorubicin, was less potent than daunorubicin at inhibiting caffeine-induced Ca(2+) release. These data suggest anthracyclines and their metabolites may produce cardiotoxicity through free-radical independent, concentration-dependent effects on SR Ca(2+) release. These effects involve either inhibition or stimulation of SR Ca(2+) release and are partly dependent upon the presence of the quinone moiety.
authors.affiliation: Pharmacology and Gerontology Unit, Veterans Affairs Medical Center, Boise, Idaho 83702, USA. ricko@micron.net
authors.forename: R D
authors.initials: RD
authors.lastname: Olson
authors.forename: X
authors.initials: X
authors.lastname: Li
authors.forename: P
authors.initials: P
authors.lastname: Palade
authors.forename: S E
authors.initials: SE
authors.lastname: Shadle
authors.forename: P S
authors.initials: PS
authors.lastname: Mushlin
authors.forename: H A
authors.initials: HA
authors.lastname: Gambliel
authors.forename: M
authors.initials: M
authors.lastname: Fill
authors.forename: R J
authors.initials: RJ
authors.lastname: Boucek
authors.forename: B J
authors.initials: BJ
authors.lastname: Cusack
mesh_terms: D000818:Animals; D000903:Antibiotics, Antineoplastic / Q000494:pharmacology*; D002110:Caffeine / Q000494:pharmacology; D002118:Calcium / Q000378:metabolism*; D003630:Daunorubicin / Q000031:analogs & derivatives* / Q000494:pharmacology; D004229:Dithiothreitol / Q000494:pharmacology; D004285:Dogs; D005260:Female; D066298:In Vitro Techniques; D008297:Male; D008861:Microsomes / Q000187:drug effects / Q000378:metabolism; D012519:Sarcoplasmic Reticulum / Q000187:drug effects / Q000378:metabolism*; D013439:Sulfhydryl Reagents / Q000494:pharmacology
chemical_list: D000903:Antibiotics, Antineoplastic; D013439:Sulfhydryl Reagents; D002110:Caffeine; C018979:5-iminodaunorubicin; D002118:Calcium; D004229:Dithiothreitol; C000847:daunorubicinol; D003630:Daunorubicin